Annual Cash & Cash Equivalents
$51.70 M
-$29.61 M-36.41%
December 31, 2023
Summary
- As of February 10, 2025, LAB annual cash & cash equivalents is $51.70 million, with the most recent change of -$29.61 million (-36.41%) on December 31, 2023.
- During the last 3 years, LAB annual cash & cash equivalents has fallen by -$16.82 million (-24.54%).
- LAB annual cash & cash equivalents is now -45.80% below its all-time high of $95.40 million, reached on December 1, 2018.
Performance
LAB Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$210.65 M
-$59.16 M-21.93%
September 30, 2024
Summary
- As of February 10, 2025, LAB quarterly cash and cash equivalents is $210.65 million, with the most recent change of -$59.16 million (-21.93%) on September 30, 2024.
- Over the past year, LAB quarterly cash and cash equivalents has increased by +$158.94 million (+307.41%).
- LAB quarterly cash and cash equivalents is now -26.62% below its all-time high of $287.06 million, reached on March 31, 2024.
Performance
LAB Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
LAB Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -36.4% | +307.4% |
| 3 y3 years | -24.5% | +48.0% |
| 5 y5 years | -45.8% | +48.0% |
LAB Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -36.4% | +81.7% | -26.6% | +640.4% |
| 5 y | 5-year | -36.4% | +138.7% | -26.6% | +872.5% |
| alltime | all time | -45.8% | +803.4% | -26.6% | +4044.2% |
Standard BioTools Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $210.65 M(-21.9%) |
| Jun 2024 | - | $269.81 M(-6.0%) |
| Mar 2024 | - | $287.06 M(+455.2%) |
| Dec 2023 | $51.70 M(-36.4%) | $51.70 M(-35.1%) |
| Sep 2023 | - | $79.66 M(-44.0%) |
| Jun 2023 | - | $142.30 M(+25.2%) |
| Mar 2023 | - | $113.66 M(+39.8%) |
| Dec 2022 | $81.31 M(+185.8%) | $81.31 M(+35.1%) |
| Sep 2022 | - | $60.20 M(-19.0%) |
| Jun 2022 | - | $74.36 M(+148.0%) |
| Mar 2022 | - | $29.98 M(+5.4%) |
| Dec 2021 | $28.45 M(-58.5%) | $28.45 M(-2.9%) |
| Sep 2021 | - | $29.31 M(-5.0%) |
| Jun 2021 | - | $30.86 M(-38.0%) |
| Mar 2021 | - | $49.74 M(-27.4%) |
| Dec 2020 | $68.52 M(+216.3%) | - |
| Dec 2020 | - | $68.52 M(-5.3%) |
| Sep 2020 | - | $72.34 M(+68.4%) |
| Jun 2020 | - | $42.97 M(+22.8%) |
| Mar 2020 | - | $34.99 M(+61.5%) |
| Dec 2019 | $21.66 M(-77.3%) | - |
| Dec 2019 | - | $21.66 M(-16.3%) |
| Sep 2019 | - | $25.89 M(+7.7%) |
| Jun 2019 | - | $24.05 M(-63.4%) |
| Mar 2019 | - | $65.63 M(-31.2%) |
| Dec 2018 | $95.40 M(+64.3%) | $95.40 M(+166.3%) |
| Sep 2018 | - | $35.83 M(-9.1%) |
| Jun 2018 | - | $39.42 M(-6.1%) |
| Mar 2018 | - | $41.97 M(-27.7%) |
| Dec 2017 | $58.06 M | $58.06 M(-4.7%) |
| Sep 2017 | - | $60.94 M(+53.9%) |
| Jun 2017 | - | $39.60 M(-10.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | - | $44.10 M(+25.8%) |
| Dec 2016 | $35.05 M(+20.4%) | $35.05 M(+8.5%) |
| Sep 2016 | - | $32.31 M(-10.0%) |
| Jun 2016 | - | $35.90 M(-16.2%) |
| Mar 2016 | - | $42.85 M(+47.2%) |
| Dec 2015 | $29.12 M(-13.6%) | $29.12 M(+1.0%) |
| Sep 2015 | - | $28.82 M(+21.4%) |
| Jun 2015 | - | $23.75 M(-35.8%) |
| Mar 2015 | - | $36.98 M(+9.7%) |
| Dec 2014 | $33.71 M(-4.4%) | $33.71 M(+9.0%) |
| Sep 2014 | - | $30.94 M(-29.2%) |
| Jun 2014 | - | $43.68 M(-56.8%) |
| Mar 2014 | - | $101.02 M(+186.5%) |
| Dec 2013 | $35.26 M(-39.9%) | $35.26 M(+75.4%) |
| Sep 2013 | - | $20.10 M(-37.8%) |
| Jun 2013 | - | $32.29 M(-47.8%) |
| Mar 2013 | - | $61.81 M(+5.4%) |
| Dec 2012 | $58.65 M(+332.7%) | $58.65 M(-11.2%) |
| Sep 2012 | - | $66.01 M(+569.9%) |
| Jun 2012 | - | $9.85 M(+16.0%) |
| Mar 2012 | - | $8.50 M(-37.3%) |
| Dec 2011 | $13.55 M(+136.8%) | $13.55 M(+14.1%) |
| Sep 2011 | - | $11.88 M(+17.3%) |
| Jun 2011 | - | $10.13 M(-81.9%) |
| Mar 2011 | - | $55.83 M(+875.6%) |
| Dec 2010 | $5.72 M(-60.8%) | $5.72 M(+12.6%) |
| Sep 2010 | - | $5.08 M(-65.2%) |
| Dec 2009 | $14.60 M(-17.9%) | $14.60 M(-17.9%) |
| Dec 2008 | $17.80 M(-47.8%) | $17.80 M(-38.6%) |
| Jun 2008 | - | $28.97 M(-15.0%) |
| Dec 2007 | $34.08 M(+36.2%) | $34.08 M |
| Dec 2006 | $25.02 M | - |
FAQ
- What is Standard BioTools annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Standard BioTools?
- What is Standard BioTools annual cash & cash equivalents year-on-year change?
- What is Standard BioTools quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Standard BioTools?
- What is Standard BioTools quarterly cash and cash equivalents year-on-year change?
What is Standard BioTools annual cash & cash equivalents?
The current annual cash & cash equivalents of LAB is $51.70 M
What is the all time high annual cash & cash equivalents for Standard BioTools?
Standard BioTools all-time high annual cash & cash equivalents is $95.40 M
What is Standard BioTools annual cash & cash equivalents year-on-year change?
Over the past year, LAB annual cash & cash equivalents has changed by -$29.61 M (-36.41%)
What is Standard BioTools quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LAB is $210.65 M
What is the all time high quarterly cash and cash equivalents for Standard BioTools?
Standard BioTools all-time high quarterly cash and cash equivalents is $287.06 M
What is Standard BioTools quarterly cash and cash equivalents year-on-year change?
Over the past year, LAB quarterly cash and cash equivalents has changed by +$158.94 M (+307.41%)